Ardelyx, Inc. Overview
Pro stress-test →Ardelyx is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative medicines that meet significant unmet medical needs. Its flagship therapies IBSRELA treat irritable bowel syndrome with constipation, while XPHOZAH helps dialysis patients manage chronic kidney disease. The company achieved exceptional commercial momentum in 2025 with strong revenue growth.
Strategic Profile
Pro stress-test →Ardelyx has developed a platform enabling discovery of new biological mechanisms to develop potent and efficacious therapies that minimize side effects and drug-drug interactions. The company expects IBSRELA to achieve $1 billion in annual revenue in 2029, with further growth thereafter. It partners with pharmaceutical entities in Canada, China, and Japan for international expansion.
Competitive Landscape
Pro stress-test →Ardelyx operates in the gastrointestinal and chronic kidney disease therapeutics markets. Competitors include established players with hyperphosphatemia and IBS-C treatments, but Ardelyx's first-in-class NHE3 inhibitor mechanism and strong commercial execution provide differentiation. The company faces competition from Shire/Takeda (constipation agents) and other phosphate binder manufacturers.
Industry Context
Ardelyx, Inc. operates in Biopharmaceuticals (GI Therapeutics & Nephrology).
Key facts
Headquarters: Waltham, US · Revenue: $407.3M · Market cap: $1.71B